Vitamin D and Marine n-3 Fatty Acids for Autoimmune Disease Prevention: Outcomes Two Years After Completion of a Double-Blind, Placebo-Controlled Trial.

What Was Tested

The paper reports a study of Vitamin D, K2, Magnesium and Zinc, published as a randomized controlled trial.

The researchers aimed to confirm further AD cases arising during and after randomization and assess sustained effects with two years of postintervention observation.

Who Took Part

The abstract describes 12,786 men taking part.

By PubMed's age tags, the people studied were middle-aged adults and older adults, both men and women.

Of the 12,786 men aged ≥50 and 13,085 women aged ≥55 initially randomized, the researchers observed surviving and willing participants for two more years.

The researchers continued to confirm annual participant-reported new AD by medical record review.

How the Study Was Run

The researchers set it up as a randomized, double-blind and placebo-controlled study.

Random assignment meant chance, not the researchers, decided who got Vitamin D, K2, Magnesium and Zinc and who got the comparison, which limits bias.

Neither the men nor the staff measuring them knew who was on Vitamin D, K2, Magnesium and Zinc, so expectations could not easily colour the readings.

The comparison arm used a placebo, so changes seen with Vitamin D, K2, Magnesium and Zinc could be set against what happens without it.

Cox models calculated HRs for all confirmed incident AD, (and secondary endpoints, including probable cases, and individual ADs), during the observational and randomized periods.

What Was Measured

The subject headings attached to it are Fatty Acids, Omega-3, Vitamin D, Autoimmune Diseases, Dietary Supplements, Incidence and Proportional Hazards Models.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in 12,786 men.

With several hundred people or more, it is a fairly large study for this kind of research.

The abstract goes on to report its results in about 4 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2024 (Arthritis & rheumatology (Hoboken, N.J.)), a journal based in United States.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.